Skip to main content

Table 1 Comparisons of differences between patients with community-acquired K. pneumoniae bacteremia and control group

From: Aspirin enhances opsonophagocytosis and is associated to a lower risk for Klebsiella pneumoniaeinvasive syndrome

 

Community-acquired K. pneumoniaebacteremia

   

Variable

Invasive syndrome (%)

   
 

Yes (n = 76)

No (n = 332)

pvalue

Control (%) (n = 76)

pvalue+

Hypermucoviscosity phenotype of K. pneumoniae

69 (90.8)

78 (23.5)

< 0.01*

  

Male

40 (52.6)

150 (45.2)

0.25

40 (52.6)

0.99

Age ≥ 60 yrs

39 (51.3)

128 (38.6)

0.05

39 (51.3)

0.99

Diabetes mellitus (DM)

41 (53.9)

134 (40.4)

0.04

25 (32.9)

0.01

DM with poor glycemic control (HbA1c ≥ 9%)

32 (42.1)

75 (22.6)

< 0.01*

17 (22.4)

0.02

Cardiovascular diseases

17 (22.4)

65 (19.6)

0.69

21 (27.6)

0.57

Liver cirrhosis

5 (6.6)

45 (13.6)

0.12

10 (13.2)

0.28

Chronic renal failure

10 (13.2)

35 (10.5)

0.54

18 (23.7)

0.14

Malignancy

4 (5.3)

33 (9.9)

0.27

18 (23.7)

< 0.01

Biliary tract diseases

2 (2.6)

20 (6.0)

0.39

8 (10.5)

0.10

Absence of underlying diseases

12 (15.8)

44 (13.3)

0.69

9 (11.8)

0.64

Therapy in the month prior to the infection

     

  Proton-pump inhibitors

8 (10.5)

24 (7.2)

0.47

15 (19.7)

0.17

  Aspirin

2 (2.6)

56 (16.9)

< 0.01*

8 (10.5)

0.10

  Antibiotics

5 (6.6)

28 (8.4)

0.76

12 (15.8)

0.12

  1. +Age-matched analysis (K. pneumoniae invasive syndrome vs. control group).
  2. *Results of multivariate analysis indicated that community-acquired K. pneumoniae bacteremic patients who were infected by strains expressing the hypermucoviscosity phenotype (odds ratio [OR], 31.07; 95% confidence interval [CI], 13.55-71.22; p < 0.01) and diabetic patients with poor glycemic control (OR, 2.46; 95% CI, 1.27-4.77; p < 0.01) were at increased risk, whereas those who had recent therapy with aspirin (OR, 0.17; 95% CI, 0.04-0.79; p = 0.02) were at lower risk of acquiring K. pneumoniae-associated invasive syndrome.